{
  "abstract": "Long-term oxygen therapy (LTOT) is provided in the home for patients with chronic obstructive pulmonary disease (COPD) who present with resting hypoxaemia (SpO2 <88%, PaO2 <60 mm Hg (8 kPa)). In the USA, LTOT is provided to approximately 1.5 million adults at an annual cost of ~$2 billion.1 The evidence base for LTOT remains two landmark studies from four decades ago, demonstrating an apparent dose–response relationship between the daily duration of therapy and mortality.2 3 LTOT is commonly referred to as ‘home’ oxygen therapy which belies the fact that while the modality is provided in the home, the intent is to allow subjects mobility, a return to a more active life and travel outside the home.4",
  "authors": [
    {
      "affiliations": [
        "Surgery, University of Cincinnati, Cincinnati, Ohio, USA"
      ],
      "name": "Richard D Branson"
    }
  ],
  "title": "Enhancing home oxygen therapy: automation to facilitate ambulation",
  "uid": "0f7edcf3-2b6f-5e85-9a5f-f34d02b5c975"
}